Delcath Systems, Inc. (DCTH): Price and Financial Metrics
DCTH Price/Volume Stats
| Current price | $5.29 | 52-week high | $7.99 |
| Prev. close | $5.45 | 52-week low | $2.25 |
| Day low | $5.29 | Volume | 5,896 |
| Day high | $5.38 | Avg. volume | 222,636 |
| 50-day MA | $4.54 | Dividend yield | N/A |
| 200-day MA | $4.13 | Market Cap | 134.57M |
DCTH Stock Price Chart Interactive Chart >
Delcath Systems, Inc. (DCTH) Company Bio
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Latest DCTH News From Around the Web
Below are the latest news stories about DELCATH SYSTEMS INC that investors may wish to consider to help them evaluate DCTH as an investment opportunity.
Insider Buying: Chief Medical Officer Vojo Vukovic Acquires 40,000 Shares of Delcath Systems ...In a notable insider transaction, Chief Medical Officer Vojo Vukovic has recently increased his stake in Delcath Systems Inc (NASDAQ:DCTH) by purchasing 40,000 shares of the company's stock. |
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma ResearchDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Melanoma Research. The publication, entitled "Quality of Life After Melphalan Hepatic Perfusion for Uveal Melanoma", was based on an independent clinical study conducted by investigators from University Hospital Southampton, UK and focused on the impact of melphalan percutaneous hepatic |
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of five individuals. |
Delcath Systems Reports Third Quarter 2023 Results and Provides Business UpdateDelcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023. |
Delcath Systems to Host Third Quarter 2023 Results CallDelcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. |
DCTH Price Returns
| 1-mo | 14.75% |
| 3-mo | 19.14% |
| 6-mo | 61.28% |
| 1-year | -7.03% |
| 3-year | -55.55% |
| 5-year | -93.48% |
| YTD | 27.16% |
| 2023 | 15.56% |
| 2022 | -53.55% |
| 2021 | -56.75% |
| 2020 | -15.67% |
| 2019 | -89.16% |
Loading social stream, please wait...